Company: MDCXW
Filing Date: 2025-11-19
Form Type: S-1
Source: 0001062993-25-016962
Chunk: 268

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-19
Form: S-1
Chunk 268
---
500 aggregate principal amount of 2025 Convertible Notes on May 3, 2024.

The Registrant issued approximately 2,770,047 common shares on June 28, 2024, including 1,461,250 common shares issued at $4.00 per share in the 2024 Equity Offering, 1,293,125 common shares issued upon conversion of the 2025 Convertible Notes at a conversion price of $4.00 per share and approximately 15,672 common shares issued in respect of accrued and unpaid interest on the 2025 Convertible Notes at a price of C$3.36 per share.

The Registrant issued 105,840 common shares to Yorkville as commitment shares pursuant to the SEPA on February 10, 2025. As of October 21, 2025, the Registrant has sold an additional 2,637,702 common shares to Yorkville pursuant to the SEPA for gross proceeds of approximately $6.2 million.

The Registrant issued 1,490,000 units, each unit consisting of one common share and one warrant to purchase one common share, on March 10, 2025 pursuant to Tier II of Regulation A under the Securities Act ("Regulation A"). As of November 7, 2025, the Registrant has issued 1,473,800 common shares upon the exercise of such warrants pursuant to Regulation A.

The Registrant issued 2,680,000 Private Warrants to Armistice on July 15, 2025.

The Registrant issued 125,000 and 20,000 common shares upon the exercise of 125,000 and 20,000 stock options on August 13, 2025, with exercise prices of C$1.16 and C$3.95, respectively.

The Registrant issued 1,603,164 common shares on August 29, 2025 as partial consideration for its acquisition of Antev Limited.

Item 16. Exhibits and Financial Statement Schedules

(a) The Exhibit Index is hereby incorporated herein by reference.

(b) Financial Statement Schedules.

All schedules have been omitted because they are not required, are not applicable or the information is otherwise set forth in the Financial Statements and related notes thereto.

Item 17. Undertakings

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise,